In non-small cell lung cancer (NSCLC), EGFR activating mutations, such as L858R, L861Q, and exon 19 deletions, are predictive of disease responsiveness to targeted therapy using tyrosine kinase inhibitors, while the presence of the EGFR T790M mutation is associated with tumor resistance to TKIs.
This application note outlines the development of two multiplex digital PCR assays to detect and quantify these mutations in single tests without sacrificing the precision and reliability of the results. The two 3-color digital PCR panels were evaluated on mutant DNA extracted from NSCLC patients and compared to next generation sequencing measurements. The measured mutant allelic EGFR fractions displayed a strong correlation.
Offered Free by: Stilla Technologies
See All Resources from: Stilla Technologies
This download should complete shortly. If the resource doesn't automatically download, please, click here.